Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 7Withdrawn 2Not yet recruiting 2Active not recruiting 2Terminated 1No longer available 1

Sponsor Class

OTHER_GOV 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

GastroEsophageal Cancer 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × bemarituzumab × Clear all
NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06978062 2025-06-05

NeoBEMA

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

GastroEsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡